Laboratorios Richmond SACIF

Laboratorios Richmond SACIF EBITDA per Share

The EBITDA per Share of Laboratorios Richmond SACIF (RICH.BA) as of Nov 22, 2026 is 256.98 ARS. In the previous year, EBITDA per Share was 84.48 ARS — a change of 204.21% (higher).

EBITDA per Share

256.98ARS

YoY

204.21%

Last updated:

EBITDA per Share of Laboratorios Richmond SACIF is 2024 256.98 ARS. EBITDA per Share of Laboratorios Richmond SACIF was 2023 84.48 ARS. It decreases by 204.21% higher compared to the previous year.

The Laboratorios Richmond SACIF EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2017
2.43 ARS
Jan 1, 2018
2.14 ARS
Jan 1, 2019
13.16 ARS
Jan 1, 2020
28.84 ARS
Jan 1, 2021
55.62 ARS
Jan 1, 2022
42.90 ARS
Jan 1, 2023
84.48 ARS
Jan 1, 2024
256.98 ARS
The Laboratorios Richmond SACIF EBITDA per Share history
YEAREBITDA per ShareYoY
256.98ARS+204.21%
84.48ARS+96.92%
42.90ARS-22.88%
55.62ARS+92.90%
28.84ARS+119.09%
13.16ARS+514.93%
2.14ARS-11.97%
2.43ARS-33.72%
3.67ARS+142.30%
1.51ARS+65.60%
0.91ARS—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Laboratorios Richmond SACIF Stock analysis

What does Laboratorios Richmond SACIF do? Laboratorios Richmond SACIF is a specialized pharmaceutical company focused on the manufacturing and marketing of medications. It was founded in 1935 and is headquartered in Buenos Aires, Argentina. The company has extensive experience in the development of medications and biological products, with expertise in pharmaceutical research and development. It has various business divisions including generics, biological medications, vaccines, oncology medications, and medical devices. The company's products range from simple painkillers and antihistamines to important medications for treating cancer and HIV. Richmond SACIF also manufactures vaccines against diseases such as Hepatitis A and B, polio, influenza, tetanus, and other infectious diseases. Additionally, the company produces a wide range of medications for treating different types of cancer and offers medical instruments and surgical devices. Its business model focuses on innovation and meeting the needs of patients, investing in research and development to develop new and innovative products. The company also has strict quality control measures to ensure the highest pharmaceutical standards. With its rich history and broad range of products, Laboratorios Richmond SACIF is a key player in the global pharmaceutical market and will continue to play an important role in improving the health of people worldwide. Laboratorios Richmond SACIF is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Laboratorios Richmond SACIF stock

EBITDA per Share of Laboratorios Richmond SACIF is 256.98 ARS in 2024.

EBITDA per Share of Laboratorios Richmond SACIF changed from 84.48 ARS to 256.98 ARS, representing a 204.21% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Laboratorios Richmond SACIF since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Laboratorios Richmond SACIF

All Key Metrics — Laboratorios Richmond SACIF